Qiagen inks deal to buy Corbett

Qiagen is buying Corbett Life Science for $70 million down in cash and stock and another $65 million in milestones. Corbett manufactures and distributes life sciences instrumentation. Corbett is best known for the first rotary, real-time PCR cycler system--the Rotor-Gene. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.